Morphometry in evaluating large cell malignant lymphomas in lymph node biopsies.

M S Mihailovici; S Roznovanu; C Cămărniceanu

PubMed · 2530444

Morphometry in evaluating large cell malignant lymphomas in lymph node biopsies.

M S Mihailovici·S Roznovanu·C Cămărniceanu

Abstract

The values of some morphometric cell parameters were analysed in 12 cases of large cell non-Hodgkin's lymphoma (centroblastic and immunoblastic lymphoma and histiocytic sarcomas) in order to test the utility of the morphometric method as an additional element to the histologic diagnosis and to its further accuracy. The nuclear and nucleolar area, the number of nucleoli per nuclear cross section and the nucleus to nucleolus ratio were investigated. The morphometric data were obtained on histograms using the Giemsa stained sections. Mean values and standard deviations were calculated and statistically analyzed. Statistical evaluation of data showed significant differences in the three groups. Our results proved the usefulness of the morphometric method as a helpful technique of differentiating the large cell malignant lymphomas.

Explore related subjects

B-Lymphocytes Biopsy Cell Nucleolus Cell Nucleus Diagnosis, Differential Humans Lymph Nodes Lymphoma, Non-Hodgkin Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

M S Mihailovici, S Roznovanu, C Cămărniceanu. Morphometry in evaluating large cell malignant lymphomas in lymph node biopsies.. https://pubmed.ncbi.nlm.nih.gov/2530444/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1998

Expression of proteins controlling transbilayer movement of plasma membrane phospholipids in the B lymphocytes from a patient with Scott syndrome.

Scott syndrome is a rare inherited bleeding disorder in which platelets and other blood cells fail to promote normal assembly of the membrane-stabilized proteases of the plasma coagulation system. The defect in Scott blood cells is known to reflect inability to mobilize phosphatidylserine from inner plasma membrane leaflet to the cell surface in response to an elevation of Ca2+ at the endofacial surface. To gain insight into the molecular basis of this membrane defect, we examined the expression in Scott cells of plasma membrane proteins that have been implicated to participate in the accelerated transbilayer movement of plasma membrane PL. By both reverse transcriptase-polymerase chain reaction (RT-PCR) and functional assay, the level of expression of the multidrug resistance (MDR)1 and MDR3 P-glycoproteins in immortalized B-lymphoblast cell lines from the patient with Scott syndrome were indistinguishable from matched cell lines derived from normal controls. Whereas the plasma membrane of Scott cells are insensitive to activation of the plasma membrane PL scramblase pathway, it had been shown that PL scramblase protein isolated from detergent-solubilized Scott erythrocytes exhibits normal function when incorporated into proteoliposomes (Stout JG, Basse F, Luhm RA, Weiss HJ, Wiedmer T, Sims PJ: J Clin Invest 99:2232, 1997). Consistent with this finding in Scott erythrocytes, we found that Scott lymphoblasts expressed normal levels of PL scramblase mRNA and protein, and that the deduced sequence of PL scramblase in Scott cells is identical to that of normal controls. These data suggest that the defect in Scott syndrome is related either to aberrant posttranslational processing of the PL scramblase polypeptide or to a defect or deficiency in an unknown cofactor that is required for normal expression of plasma membrane PL scramblase function in situ, or alternatively, reflects the presence of a detergent-dissociable inhibitor of this pathway.

B-Lymphocytes↗

PubMed1998

Serum factors and the cellular redox status regulate cellular responsiveness to MHC class II-triggered homotypic B cell adhesion.

Cross-linking the major histocompatibility complex (MHC) class II (MHC-II) by their cognate ligands including mAb induces homotypic cell adhesion. It has been shown that merely surface MHC-II expression is insufficient to induce the response. We found that MHC-II-triggered cell adhesion in human B cell lines was absent when serum was removed from medium. Even in the presence of serum, the response was prevented when cells were treated with the glutathione synthesis inhibitor, buthionine sulfoximine, an irreversible catalase inhibitor, aminotriazole, and H2O2. Flow cytometrical analysis showed that these changes in cellular responsiveness were unlikely to be merely the result of altered surface Ag expression. In addition, the response was independent of the two major lymphocyte adhesion receptors, LFA-1 and intercellular adhesion molecule-1 (ICAM-1). These findings suggest that serum- and redox-sensitive intracellular events regulate cellular responsiveness to MHC-II-triggered LFA-1/ICAM-1-independent cell adhesion independently of differentiation.

B-Lymphocytes↗

PubMed1998

An immune cell-selective interleukin 4 agonist.

Interleukin 4 (IL-4) is a pleiotropic cytokine. Of the cell types responsive to IL-4, T cells express one IL-4 receptor (IL-4R) type, IL-4Ralpha/IL-2Rgamma (class I IL-4R), whereas endothelial cells express another type, IL-4Ralpha/IL-13Ralpha (class II IL-4R). It was hypothesized that IL-4 variants could be generated that would be selective for cell types expressing the different IL-4Rs. A series of IL-4 muteins were generated that were substituted in the region of IL-4 implicated in interactions with IL-2Rgamma. These muteins were evaluated in T cell and endothelial cell assays. One of these muteins, containing the mutation Arg-121 to Glu (IL-4/R121E), exhibited complete biological selectivity for T cells, B cells, and monocytes, but showed no activity on endothelial cells. Receptor binding studies indicated that IL-4/R121E retained physical interaction with IL-2Rgamma but not IL-13Ralpha; consistent with this observation, IL-4/R121E was an antagonist of IL-4-induced activity on endothelial cells. IL-4/R121E exhibits a spectrum of activities in vitro that suggest utility in the treatment of certain autoimmune diseases.

B-Lymphocytes↗